Jeff Bezos Backed Grail Before It Lost Half Its Value. Here's Whether He Was Early -- or Just Wrong.

Grail shares plunged after reporting mixed clinical trial results, but have partially rebounded as investors gained confidence in management’s plan to extract value from its Galleri test. The news signal remains mixed—initial outcomes pressured sentiment, while the longer-term strategy is providing near-term support.

Analysis

Grail shares plunged after reporting mixed clinical trial results, but have partially rebounded as investors gained confidence in management’s plan to extract value from its Galleri test. The news signal remains mixed—initial outcomes pressured sentiment, while the longer-term strategy is providing near-term support.